Celtic Lux Holdings Acquires 10.1 Million Alvotech Shares at $3.75
Celtic Lux Holdings S.a. r.l. acquired 10,133,333 shares in Alvotech at a price of $3.75 per share. The transaction date was June 16, 2026.
Alvotech announced on June 22, 2026, that Celtic Lux Holdings S.a. r.l. acquired 10,133,333 shares in the company. The acquisition took place at a price of $3.75 per share, with the transaction date recorded as June 16, 2026.
The filing was made with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF), as is standard for transactions by managers and closely associated persons. Celtic Lux Holdings S.a. r.l. was formerly known as Alvogen Lux Holdings S.a. r.l.
Alvotech is a biopharmaceutical company focused on the development and manufacturing of biosimilar medicines. Biosimilars are intended to offer more affordable alternatives to existing biologic therapies across various therapeutic areas. Such disclosures are common following significant share transactions.
The company did not provide further commentary on the specific implications of this transaction in its announcement, which included a copy of the notification filed with the CSSF.